PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Abrocitinib
Drug: Omeprazole
Drug: Caffeine
Drug: Efavirenz

First Posted Date: 2021-10-05

Last Posted Date: 2024-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT05067439

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States

A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06650833
Drug: Ethinyl estradiol (EE) and levonogestrel (LN)

First Posted Date: 2021-10-01

Last Posted Date: 2023-10-02

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05064332

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07321332/ritonavir + Dabigatran
Drug: Ritonavir + Dabigatran
Drug: Dabigatran

First Posted Date: 2021-10-01

Last Posted Date: 2024-03-29

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT05064800

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Phase 1

Terminated

Conditions: Renal Cell Cancer
Squamous Cell Carcinoma
Sarcoma
Colorectal Cancer
Bladder Cancer
Head and Neck Cancer
Melanoma
Non-Small-Cell Lung Cancer
Hepatocellular Cancer
Ovarian Cancer

Interventions: Biological: PF-07263689
Biological: Sasanlimab

First Posted Date: 2021-09-29

Last Posted Date: 2024-04-12

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT05061537

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
CUMC Research Pharmacy, New York, New York, United States

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Etrasimod
Drug: Placebo

First Posted Date: 2021-09-29

Last Posted Date: 2024-10-29

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT05061446

Locations: 🇯🇵
NHO Hirosaki General Medical Center, Hirosaki-shi, Aomori-ken, Japan
🇯🇵
Our Lady of the Snow St. Mary's Hospital, Kurume, Fukuoka, Japan
🇯🇵
Kudo Internist Heart Clinic, Morioka-shi, Iwate-ken, Japan

and more 76 locations

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Recifercept

First Posted Date: 2021-09-29

Last Posted Date: 2023-04-18

Lead Sponsor: Pfizer

Registration Number: NCT05061277

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3

Active, not recruiting

Conditions: Advanced Malignancies
NSCLC
Ovarian Cancer
Urothelial Cancer
Solid Tumors

Interventions: Drug: Avelumab
Drug: CMP 001
Drug: Lorlatanib
Drug: Talazoparib
Drug: Pemetrexed
Drug: Axitinib
Drug: Utomilumab
Drug: PF04518600

First Posted Date: 2021-09-28

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 67

Registration Number: NCT05059522

Locations: 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇷🇺
Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation
🇺🇸
MSK Monmouth, Middletown, New Jersey, United States

and more 66 locations

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Biological: mIRV
Biological: bIRV AB
Biological: qIRV
Biological: QIV
Biological: bIRV AA
Biological: bIRV BB

First Posted Date: 2021-09-22

Last Posted Date: 2024-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 1158

Registration Number: NCT05052697

Locations: 🇺🇸
NYU Langone Cardiology Associates, Delray Beach, Florida, United States
🇺🇸
Robert B. Pritt, DO, Fort Myers, Florida, United States
🇺🇸
Orange County Research Center, Tustin, California, United States

and more 89 locations

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07304814

First Posted Date: 2021-09-20

Last Posted Date: 2022-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 5

Registration Number: NCT05050682

Locations: 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: PF-07321332
Drug: Placebo for PF-07321332
Drug: Placebo for Ritonavir
Drug: Ritonavir

First Posted Date: 2021-09-17

Last Posted Date: 2023-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 2954

Registration Number: NCT05047601

Locations: 🇺🇸
Accellacare, Ames, Iowa, United States
🇨🇴
Clinica de la Costa LTDA., Barranquilla, Atlantico, Colombia
🇭🇺
Medifarma-98 Kft., Nyiregyhaza, Hungary

and more 165 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy